This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Top 10 Articles, Videos on TheStreet

NEW YORK ( TheStreet) -- In case you missed them, here are the top 10 most popular articles and videos on TheStreet today. Sign up for free email delivery of our daily Top 10.

Data-Based IPOs: Splunk, Infoblox, Proofpoint
Debra Borchardt
It's California dreaming for these three data-based IPOs with Splunk looking the strongest.

5 Stocks Insiders Love Right Now
Roberto Pedone
Insiders at these companies have been scooping up shares of their own stock lately. (Stocks mentioned include: SEAC, COMV)

Windows Trips Up H-P's Giant 'iPad' Bet
Jonathan Blum
The HP TouchSmart 9300 PC puts iPad-like touch on your desktop. But it's still too much Microsoft, too little Apple.

Stocks Hold Gains After Mixed Economic Data
Andrea Tse
Wall Street wavers after a smooth Spanish bond auction and a solid round of earnings reports is followed by a series of mixed economic indicators.

Thursday's Earnings Roundup: BAC, MS, DD, TRV, DHR, VZ, EMC, NOK
Alexandra Zendrian
These companies reported earnings on Thursday before the bell.

EMC Profit Climbs on Cloud, Big Data
James Rogers
Shrugging off recent tech sector unease, EMC reports solid first-quarter results.

Qualcomm's Pain May Be Apple's Gain
Chris Ciaccia
Qualcomm said supply of some of its chips aren't able to keep up with demand, which likely indicates Apple continues to do exceptionally well.

Molycorp Inc. Stock Upgraded (MCP)
TheStreet Wire
Molycorp (NYSE:MCP) has been upgraded by TheStreet Ratings from a sell to hold.

Bank of America Beats Estimates in Noisy Quarter (Update 2)
Dan Freed
Legacy mortgage issues continue to weigh.

Human Genome Rejects $2.6B Bid From GlaxoSmithKline (Update 1)
Adam Feuerstein
Human Genome Sciences rejects a $2.6 billion unsolicited offer from GlaxoSmithKline.

This article was written by a staff member of TheStreet.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AAPL $132.54 0.88%
FB $80.54 0.07%
GOOG $540.11 -0.44%
TSLA $247.73 0.86%
YHOO $43.48 -0.44%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs